The company's innovative qualities may pay rich dividends down the road.

The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains ...

People living with hereditary angioedema, a rare genetic condition that triggers unpredictable and sometimes life-threatening ...

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, ...

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 1.81% at $60.77. This change lagged the S&P 500's daily ...

Researchers are investigating the potential of CRISPR in relation to Down syndrome.

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...